Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
AstraZeneca Takeda Global Research & Development Center, Inc. |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00252694 |
The primary objective is to determine whether candesartan, compared to placebo reduces the progression of diabetic retinopathy in normoalbuminuric type 2 diabetic patients with retinopathy.
The secondary objective is to determine whether candesartan, compared to placebo, reduces the incidence of clinically significant macular oedema (CSME) and/or proliferative diabetic retinopathy (PDR) and beneficially influences the rate change in urinary albumin excretion rate (UAER).
This study is part of the DIRECT Programme also including a primary prevention study of diabetic retinopathy in type 1 diabetes and a secondary prevention study in type 1 diabetes. The primary objective for all three pooled studies is to determine whether candesartan, compared to placebo, reduces the incidence of microalbuminuria in type 1 and type 2 diabetic patients.
Condition | Intervention | Phase |
---|---|---|
Type 2 Diabetes |
Drug: Candesartan cilexetil |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 2 Diabetic Patients With Retinopathy. |
Enrollment: | 1800 |
Study Start Date: | August 2001 |
Estimated Study Completion Date: | June 2008 |
Estimated Primary Completion Date: | February 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: No Intervention
Placebo
|
|
2: Experimental
Candesartan Cilexetil
|
Drug: Candesartan cilexetil
32 mg oral tablet
|
Ages Eligible for Study: | 37 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | D2453C00047, DIRECT, SH-AHM-0047 |
Study First Received: | November 10, 2005 |
Last Updated: | February 2, 2008 |
ClinicalTrials.gov Identifier: | NCT00252694 |
Health Authority: | Denmark: Danish Medicines Agency |
Diabetes mellitus type 2 |
Metabolic Diseases Eye Diseases Diabetes Mellitus Vascular Diseases Endocrine System Diseases Angiotensin II Diabetic Angiopathies Candesartan cilexetil |
Diabetic Retinopathy Candesartan Diabetes Mellitus, Type 2 Endocrinopathy Glucose Metabolism Disorders Metabolic disorder Retinal Diseases Diabetes Complications |
Angiotensin II Type 1 Receptor Blockers Molecular Mechanisms of Pharmacological Action Therapeutic Uses Cardiovascular Diseases |
Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions |